Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry
July 17 2019 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), announced that it has received a patent from the
Patents Registry in Hong Kong (Hong Kong Patent No. HK1204758
titled “Apparatus for Use in the Measurement of Macular Pigment
Optical Density and/or Lens Optical Density of an Eye”) for its
proprietary medical device, the MapcatSF®. The MapcatSF® measures
the macular pigment density in the human eye, thus facilitating
treatment for several ocular conditions and diseases that affect a
large number of patients.
Dr David Evans, Guardion’s Chief Science
Officer, commenting on the granting of this patent by Hong Kong,
stated, “The granting of this patent in Honk Kong represents an
important step in Guardion’s process to expand into the large Asian
markets, where evidenced-based eye care is of great interest to
both physicians and consumers. Guardion’s proprietary technologies
strengthen our position as we consider additional business
opportunities across Asia.”
Guardion previously reported that it received
trademark registration from the People’s Republic of China for its
proprietary medical food product Lumega-Z® and its medical device
the MapcatSF®.
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product, Lumega-Z®, that addresses a depleted
macular protective pigment, a known risk factor for age-related
macular degeneration (“AMD”) and a significant component of
functional vision performance. Guardion Health Sciences, Inc. has
also developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment. Information and
risk factors with respect to Guardion and its business, including
its ability to successfully develop and commercialize its
proprietary products and technologies, may be obtained in the
Company’s filings with the Securities and Exchange Commission
(“SEC”) at www.sec.gov.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. The forward-looking statements include statements
regarding the Company’s process to expand into the large Asian
markets and considering additional business opportunities across
Asia. These statements involve unknown risks and uncertainties that
may individually or materially impact the matters discussed herein
for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
expand into the large Asian markets as planned, the Company’s
ability to conclude additional business opportunities across Asia,
the Company’s ability to raise sufficient financing to implement
its business plan and the Company’s ability to successfully develop
and commercialize its proprietary products and technologies.
Readers are cautioned not to place undue reliance on these
forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company
Contact: |
Investor Relations
Contact: |
Michael Favish |
Matthew
Abenante |
Chief Executive
Officer |
Porter, LeVay &
Rose, Inc. |
Telephone: (858)
605-9055 x 201 |
Telephone: (212)
564-4700 |
E-mail: mfavish@guardionhealth.com |
E-mail: matthew@plrinvest.com |
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024